Abstract
Objective: To determine if a direct measure of instrumental activities of daily living (IADL) scale designed for use with dementia patients can detect differences between persons with mild cognitive impairment (MCI) and normal elderly control subjects (NC). Methods: This study used cross-sectional and longitudinal IADL scale data from MCI and NC subjects followed at an Alzheimers Disease Center. Results: On a 52-point scale, MCI subjects (n = 30) scored significantly lower than NC subjects (n = 30) on the IADL scale (total score 47.17 vs. 48.77 points; t (58) = 2.34, p = .011) and its Memory subscale (5.27 vs. 6.6 points; t (58) = 3.29, p = .002).Examination of annualized IADL scale change scores revealed that 50% of MCI subjects had declined by one point, compared with 29% of NC. Conclusion: A direct IADL measure for dementia patients is able to detect small differences between MCI and NC and cross-sectionally and longitudinally, but does not distinguish between groups.
Keywords: Mild cognitive impairment, IADL, Texas Functional Living Scale
Current Alzheimer Research
Title: Can a Direct IADL Measure Detect Deficits in Persons with MCI?
Volume: 6 Issue: 1
Author(s): Dani L. Binegar, Linda S. Hynan, Laura H. Lacritz, Myron F. Weiner and C. Munro Cullum
Affiliation:
Keywords: Mild cognitive impairment, IADL, Texas Functional Living Scale
Abstract: Objective: To determine if a direct measure of instrumental activities of daily living (IADL) scale designed for use with dementia patients can detect differences between persons with mild cognitive impairment (MCI) and normal elderly control subjects (NC). Methods: This study used cross-sectional and longitudinal IADL scale data from MCI and NC subjects followed at an Alzheimers Disease Center. Results: On a 52-point scale, MCI subjects (n = 30) scored significantly lower than NC subjects (n = 30) on the IADL scale (total score 47.17 vs. 48.77 points; t (58) = 2.34, p = .011) and its Memory subscale (5.27 vs. 6.6 points; t (58) = 3.29, p = .002).Examination of annualized IADL scale change scores revealed that 50% of MCI subjects had declined by one point, compared with 29% of NC. Conclusion: A direct IADL measure for dementia patients is able to detect small differences between MCI and NC and cross-sectionally and longitudinally, but does not distinguish between groups.
Export Options
About this article
Cite this article as:
Binegar L. Dani, Hynan S. Linda, Lacritz H. Laura, Weiner F. Myron and Cullum Munro C., Can a Direct IADL Measure Detect Deficits in Persons with MCI?, Current Alzheimer Research 2009; 6 (1) . https://dx.doi.org/10.2174/156720509787313880
DOI https://dx.doi.org/10.2174/156720509787313880 |
Print ISSN 1567-2050 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5828 |
Call for Papers in Thematic Issues
New Advances in the Prevention, Diagnosis, Treatment, and Rehabilitation of Alzheimer's Disease
Aims and Scope: Introduction: Alzheimer's disease (AD) poses a significant global health challenge, with an increasing prevalence that demands concerted efforts to advance our understanding and strategies for prevention, diagnosis, treatment, and rehabilitation. This thematic issue aims to bring together cutting-edge research and innovative approaches from multidisciplinary perspectives to address ...read more
Current updates on the Role of Neuroinflammation in Neurodegenerative Disorders
Neuroinflammation is an invariable hallmark of chronic and acute neurodegenerative disorders and has long been considered a potential drug target for Alzheimer?s disease (AD) and dementia. Significant evidence of inflammatory processes as a feature of AD is provided by the presence of inflammatory markers in plasma, CSF and postmortem brain ...read more
Deep Learning for Advancing Alzheimer's Disease Research
Alzheimer's disease (AD) poses a significant global health challenge, with an increasing number of individuals affected yearly. Deep learning, a subfield of artificial intelligence, has shown immense potential in various domains, including healthcare. This thematic issue of Current Alzheimer Research explores the application of deep learning techniques in advancing our ...read more
Diagnostic and therapeutic biomarkers of dementia
Dementia affects 18 million people worldwide. Dementia is a syndrome of symptoms caused by brain disease, usually chronic or progressive, clinically characterized by multiple impairments of higher cortical functions such as memory, thinking, orientation, and learning. In addition, in the course of dementia, cognitive deficits are observed, which often hinder ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Signal Transduction in HIV Protein-Treated Astrocytes
Current Signal Transduction Therapy Ximelagatran - A Promising New Drug in Thromboembolic Disorders
Current Pharmaceutical Design Systems Medicine Approaches to Improving Understanding, Treatment, and Clinical Management of Neuroendocrine Prostate Cancer
Current Pharmaceutical Design Subject Index To Volume 3
Current Alzheimer Research Hematopoietic Growth Factors Support in the Elderly Cancer Patients Treated with Antiblastic Chemotherapy
Anti-Cancer Agents in Medicinal Chemistry Insulin Resistance in Brain and Possible Therapeutic Approaches
Current Vascular Pharmacology Modifiable Risk Factors for Premature Atherosclerosis in Systemic Lupus Erythematosus
Vascular Disease Prevention (Discontinued) Non-Amyloid PET Imaging Biomarkers for Neurodegeneration: Focus on Tau, Alpha-Synuclein and Neuroinflammation
Current Alzheimer Research Lipoprotein (a) Evolution: Possible Benefits and Harm. Genetic and Non-Genetic Factors Influencing its Plasma Levels
Current Medicinal Chemistry Possible Hypoxia Signaling Induced Alteration of Glucose Homeostasis in Rats Exposed to Chronic Intermittent Hypoxia - Role of Antioxidant (Vitamin C) and Ca2+ Channel Blocker (Cilnidipine)
Current Signal Transduction Therapy Mediterranean Diet and Dementia of the Alzheimer Type
Current Aging Science Performance Evaluation in Medical Image Segmentation
Current Medical Imaging Visceral Fat as Target of Highly Active Antiretroviral Therapy-Associated Metabolic Syndrome
Current Pharmaceutical Design Therapeutic Benefit and Biological Importance of Ginkgetin in the Medicine: Medicinal Importance, Pharmacological Activities and Analytical Aspects
Current Bioactive Compounds Patent Selections
Recent Patents on CNS Drug Discovery (Discontinued) ISCHEMIRs: Finding a Way Through the Obstructed Cerebral Arteries
Current Drug Targets Complementary and Alternative Medicine for the Treatment of Insomnia: An Overview of Scientific Evidence from 2008 to 2018
Current Vascular Pharmacology Pharmacogenomics in Psychiatry: Implications for Practice
Recent Patents on Biotechnology Recent Advances on the Roles of NO in Cancer and Chronic Inflammatory Disorders
Current Medicinal Chemistry Hypertensive Pharmacogenomics in African Americans
Current Pharmacogenomics